Shielded by Statute: How the Trade Secrets Exemption Became a Federal Tool for Burying Inconvenient Science
When Congress drafted the Freedom of Information Act in 1966, it included a carefully bounded provision: Exemption 4, commonly referred to as "B4," which permits agencies to withhold "trade secrets and commercial or financial information obtained from a person and privileged or confidential." The intent was modest — protect genuinely proprietary business data from competitive exposure when submitted voluntarily to regulators. What it was never designed to do was function as a blanket mechanism for concealing federally funded science that yields politically uncomfortable results.
Yet that is precisely how it is being used.
Across agencies ranging from the Environmental Protection Agency to the Food and Drug Administration to the Department of Agriculture, FOIA officers have stretched Exemption B4 far beyond its statutory boundaries. The consequence is a growing archive of suppressed findings — toxicology studies, efficacy assessments, environmental impact analyses — that taxpayers financed and that regulators cite in policymaking, yet that citizens are legally prevented from reading in full.
The Anatomy of a Loophole
To understand how the abuse operates, it is necessary to understand the legal architecture that enables it. Under the Supreme Court's 2019 ruling in Food Marketing Institute v. Argus Leader Media, the threshold for invoking B4 was significantly lowered. Previously, courts required agencies to demonstrate that disclosure would cause "substantial competitive harm" to the submitting company. After Argus Leader, the standard collapsed to a far simpler test: Was the information customarily kept private by the submitting entity? Had the government received it with an assurance of confidentiality?
In practice, this means that a corporation submitting research data to a federal agency — even research conducted entirely with public grant money — can now claim B4 protection simply by marking documents "confidential" upon submission. The agency, facing no meaningful legal obligation to push back, routinely acquiesces.
The result is a system in which the act of submitting data to the government, rather than protecting public access, actively forecloses it.
Case Patterns That Demand Scrutiny
Documented FOIA litigation reveals consistent patterns worth examining closely.
In cases involving pesticide registration data submitted to the EPA, requesters — including academic researchers and public health organizations — have repeatedly encountered B4 denials covering not merely the chemical formulations themselves, but the underlying biological and ecological study data. Regulatory decisions affecting millions of Americans rest on science that no independent researcher can verify.
Similar dynamics have emerged at the FDA, where pharmaceutical companies submit clinical trial data as part of new drug applications. While summary results may eventually appear in public-facing approval documents, the granular datasets — the raw numbers that would allow independent statisticians to audit efficacy and safety claims — are routinely withheld under B4. This is particularly troubling given that the trials generating that data were frequently subsidized through federal research grants or conducted at public universities under federal contracts.
At the USDA, agricultural biotechnology assessments have drawn similar scrutiny. Petitions seeking non-regulated status for genetically engineered crops incorporate proprietary studies that, once submitted, become functionally invisible to outside review. Public comment periods proceed on the basis of agency summaries rather than primary evidence.
In each of these contexts, the agency is not merely protecting a trade secret. It is insulating a regulatory conclusion from the independent scientific scrutiny that lends that conclusion credibility.
When "Commercial" Becomes a Shield for Government Interests
The problem is compounded when agency interests align with those of the submitting company. Career regulators, agency budgets, and interagency relationships do not exist in a vacuum. When an agency has staked its institutional credibility on a particular approval or policy position, the suppression of contradictory data serves the agency's interests as much as the corporation's.
This dynamic was visible in prolonged disputes over glyphosate toxicology assessments, where internal EPA communications — themselves obtained through litigation rather than routine disclosure — revealed significant disagreements among scientists that were not reflected in public-facing conclusions. The underlying industry-submitted studies that informed those conclusions remained shielded throughout.
It is also evident in environmental impact contexts, where energy companies submitting baseline ecological data to federal land management agencies have successfully invoked B4 to prevent that data from being independently evaluated during public comment processes — precisely the stage at which it would be most consequential.
The Legal Terrain for Challengers
Citizens and researchers who receive B4 denials are not without recourse, though the path is demanding.
The first and most important step is administrative appeal. A significant percentage of B4 denials are issued by lower-level FOIA offices without rigorous legal analysis. Appeals to the agency's FOIA Appeals Officer — or in some cases, the agency's Office of General Counsel — frequently result in partial reversals, particularly when the requester can articulate specifically why the withheld material does not meet the Argus Leader standard. Demonstrating that the information at issue was produced with federal funding, or that it was not customarily treated as confidential prior to submission, can be effective grounds.
Second, requesters should consider filing with the Office of Information Policy at the Department of Justice, which oversees government-wide FOIA compliance and has issued guidance cautioning agencies against overbroad B4 invocations. While OIP lacks enforcement authority over individual denials, formal complaints create a documented record that can support subsequent litigation.
Third, for cases involving research with significant public health or environmental implications, legal organizations specializing in government accountability — including the Government Accountability Project and the Electronic Privacy Information Center — have developed litigation strategies specifically targeting B4 overreach. Federal district courts retain jurisdiction over FOIA disputes, and judges have demonstrated increasing willingness to conduct in camera review of withheld materials rather than accepting agency declarations at face value.
Finally, congressional engagement remains an underutilized tool. The Senate and House Judiciary Committees have oversight authority over FOIA administration, and documented patterns of B4 abuse constitute precisely the kind of systemic issue that oversight hearings are designed to address.
The Deeper Accountability Question
At its core, this issue is not merely procedural. It implicates a foundational question about the relationship between public funding and public knowledge. When the federal government finances scientific inquiry — directly through grants or indirectly through regulatory mandates — and then permits the resulting data to be sequestered under a corporate confidentiality claim, it has effectively privatized a public asset.
The agencies invoking B4 in these contexts are not neutral arbiters. They are institutions with their own incentives, pressures, and relationships. The exemption, as currently applied, provides those institutions with a convenient mechanism for managing inconvenient evidence rather than confronting it.
Full disclosure — genuine, unfiltered access to the science that informs decisions affecting public health, environmental safety, and consumer protection — requires that this mechanism be challenged wherever it appears. The law provides the tools. The question is whether citizens, researchers, and their representatives are prepared to use them.